American Journal of Clinical Dermatology

Teledermatology: Current Status and Future Directions
pp. 59-64(6)
Author: Whited J.D.

The Impact of COLIPA Guidelines for Assessment of Skin Compatibility on the Development of Cosmetic Products
pp. 65-68(4)
Authors: Meloni M.; Berardesca E.

Cutaneous Reactions to Anticoagulants: Recognition and Management
pp. 69-75(7)
Authors: Harenberg J.; Hoffmann U.; Huhle G.; Winkler M.; Bayerl C.

Phase III Vehicle-Controlled, Multi-Centered Study of Topical Alitretinoin Gel 0.1% in Cutaneous AIDS-Related Kaposi's Sarcoma
pp. 77-87(11)
Authors: Bodsworth N.J.; Bloch M.; Bower M.; Donnell D.; Yocum R.

Clobetasol Propionate Foam, 0.05%
pp. 89-92(4)
Authors: Melian E.B.; Spencer C.M.; Jarvis B.

Clobetasol Propionate Foam, 0.05%: A Viewpoint by Mark Lebwohl and Amy Krupnick
pp. 93-93(1)
Authors: Lebwohl M.; Krupnick A.

Clobetasol Foam, 0.05%: A Viewpoint by H. Irving Katz
pp. 93-93(1)
Author: Katz H.I.

Calcipotriol Ointment: A Review of its Use in the Management of Psoriasis
pp. 95-120(26)
Authors: Scott L.J.; Dunn C.J.; Goa K.L.

Cutaneous Drug Reaction Case Reports: From the World Literature
pp. 121-127(7)

‘Wonder Drugs’ for Psoriasis: A Never Ending Story
pp. 129-130(2)
Author: Mrowietz U.